- Home
- TIL vs NVCT Comparison
TIL vs NVCT Comparison
Compare TIL & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- NVCT
- Stock Information
- Founded
- TIL 2018
- NVCT 2020
- Country
- TIL United States
- NVCT United States
- Employees
- TIL N/A
- NVCT N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- TIL Health Care
- NVCT Health Care
- Exchange
- TIL Nasdaq
- NVCT Nasdaq
- Market Cap
- TIL 177.1M
- NVCT 167.0M
- IPO Year
- TIL 2021
- NVCT 2022
- Fundamental
- Price
- TIL $31.50
- NVCT $6.68
- Analyst Decision
- TIL Buy
- NVCT Strong Buy
- Analyst Count
- TIL 6
- NVCT 3
- Target Price
- TIL $120.50
- NVCT $15.33
- AVG Volume (30 Days)
- TIL 109.0K
- NVCT 79.0K
- Earning Date
- TIL 08-13-2025
- NVCT 11-04-2025
- Dividend Yield
- TIL N/A
- NVCT N/A
- EPS Growth
- TIL N/A
- NVCT N/A
- EPS
- TIL N/A
- NVCT N/A
- Revenue
- TIL N/A
- NVCT N/A
- Revenue This Year
- TIL N/A
- NVCT N/A
- Revenue Next Year
- TIL N/A
- NVCT N/A
- P/E Ratio
- TIL N/A
- NVCT N/A
- Revenue Growth
- TIL N/A
- NVCT N/A
- 52 Week Low
- TIL $10.80
- NVCT $4.44
- 52 Week High
- TIL $92.00
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- TIL 61.57
- NVCT 48.98
- Support Level
- TIL $26.69
- NVCT $6.32
- Resistance Level
- TIL $28.85
- NVCT $6.90
- Average True Range (ATR)
- TIL 2.16
- NVCT 0.33
- MACD
- TIL 0.43
- NVCT 0.06
- Stochastic Oscillator
- TIL 76.70
- NVCT 72.15
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.